{
    "nctId": "NCT01996046",
    "briefTitle": "FDG PET/CT in Breast Cancer Bone Mets",
    "officialTitle": "18F-fluorodeoxyglucose (FDG) Positron Emission Tomography (PET/CT) for the Evaluation of Response to Therapy in Bone-dominant Metastatic Breast Cancer",
    "overallStatus": "ACTIVE_NOT_RECRUITING",
    "conditions": "Estrogen Receptor Positive Breast Cancer, Bone Metastases",
    "studyType": "OBSERVATIONAL",
    "phase": "N/A",
    "allocation": "N/A",
    "primaryPurpose": "N/A",
    "enrollmentCount": 75,
    "primaryOutcomeMeasure": "Progression free survival",
    "eligibilityCriteria": "Inclusion Criteria:\n\n1. Adult patients, at least 18 years of age, with a history of pathologically confirmed ER+ breast cancer\n2. Biopsy proven or clinically obvious documented bone metastases from breast cancer (with the majority of the disease burden in the bone)\n3. Patients planning to start new endocrine targeted therapy (any line of therapy is acceptable and any endocrine therapy is allowed)\n4. Willing and able to comply with scheduled visits and serial imaging procedures\n5. Agrees to allow access to clinical records regarding response to treatment and long term follow up.\n6. Be informed of the investigational nature of this study and provide written informed consent in accordance with institutional and federal guidelines\n\nExclusion Criteria:\n\n1. Women who are pregnant or breast feeding\n2. Uncontrolled diabetes mellitus (fasting glucose greater than 200 mg/dL)\n3. Inability to tolerate imaging procedures (e.g. claustrophobia, severe pain)\n4. Weight exceeding capacity of imaging table\n5. Previous treatment with radiation or surgery to a significant percentage of bony metastatic sites\n6. Treatment with marrow stimulating agents (e.g. granulocyte colony stimulating factor (GCSF)) within 3 weeks of baseline scan",
    "sex": "FEMALE",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}